Dosimetry study of a phase II multiple-dose intracavitary administration of (131)I-TM601 in adult patients with recurrent high-grade glioma.

Academic Article

Abstract

  • e13006 Background: Postoperative radiotherapy for glioma has been shown to improve survival with increased radiation doses. Dose escalation of external beam radiotherapy or brachytherapy is limited by normal brain radionecrosis. Radiolabeled targeting molecules can deliver localized radiation to tumor and reduce normal brain radionecrosis. TM601, or synthetic Chlorotoxin, is a peptide derived from scorpion venom that specifically binds to tumor cells. Here we report dosimetry results of an imaging sub-study of a phase II trial, in which weekly doses of (131)I-TM601 were infused into surgically created tumor resection cavities for 3 or 6 weeks. METHODS: Five out of 76 patients treated in a phase II trial were imaged after receiving 1, 3, or 6 doses of 40 mCi/0.8 mg (131)I-TM601 intracavitarily. For each imaging study, 5 sequential SPECT images (1-168 hour) were registered with MRI to determine the (131)I-TM601 radiation dose to the 2-cm tumor cavity margin. Five sequential body scans were also acquired to determine (131)I-TM601 radiation dose to extra-cranial organs. RESULTS: (131)I-TM601 is a rapidly penetrating and clearing radiolabeled peptide. The median residual activity in the cavity at 7 days post injection was 8.4%. Median radiation dose to the cavity margin was 121 cGy/mCi and ranged 52- 338 cGy/mCi in 5 subjects. The median coefficient of variation (intra-patient inter-fraction) for the 2-cm margin dose was 14.7% and ranged 7.1-18.9%. Median tumor cavity volume was 11.4 mL, and ranged 5.2 - 35.5 mL. There was no observed correlation between the 2-cm margin dose and the cavity volume. Median radiation dose to thyroid, kidneys, red marrow, and body was 8.3, 1.3, 0.4, and 0.6 cGy/mCi, respectively. CONCLUSIONS: Radiation dose ratio for 2-cm cavity margin-to-normal tissues was quite high. While intra-patient reproducibility was relatively good, cumulative effect of the residual activity was only meaningful within a week. These results support the multi-dose fractionation scheme for (131)I-TM601 to minimize normal tissue toxicity, including radiation necrosis, and extend continuous irradiation to clinical or sub-clinical residual tumor cells after surgery. [Table: see text].
  • Published In

    Pubmed Id

  • 10653397
  • Author List

  • Shen S; Nabors LB; Raizer JJ; Fiveash JB; Spies S; Costello R; O'Neill AM
  • Start Page

  • e13006
  • Volume

  • 27
  • Issue

  • 15_suppl